BBLG Bone Biologics Corporation

NASDAQ
$0.57

Bone Biologics Corporation (BBLG) Institutional Ownership

What the institutions did with BBLG last quarter, from their 13F filings. Counting managers rather than shares is the point: a single index fund adding to a position tells you far less than four hundred separate managers all deciding to. Positions as reported for the quarter ended June 30, 2026.

Managers compared
4
filed both this quarter and last
Managers holding
3
+0 on the quarter
Buyers
1
1 opened new
Sellers
2
1 sold out entirely
Buyer share
33.3%
of managers who traded it
Breadth
-33.3
net buyers, as a share of those trading

Only 4 managers reported a position this quarter, so the percentages above describe a very small sample.

Every manager below opens. Subscribers can see any firm's whole portfolio — every position, its weight, and what they bought, trimmed and exited last quarter.

Sign in or subscribe

Largest holders

Manager Shares % of reported
CITADEL ADVISORS LLC 23.9K 91.6%
Tower Research Capital LLC (TRC) 2.0K 7.5%
SBI Securities Co., Ltd. 230 0.9%

Largest changes

Manager Action Previous Current Change
CITADEL ADVISORS LLC New 0 23.9K +23.9K
Tower Research Capital LLC (TRC) Reduced 4.1K 2.0K -2.2K
UBS Group AG Sold Out 56 0 -56

13F filings are due 45 days after quarter end and cover long positions in U.S.-listed equities only, so this is a lagged and partial picture: shorts, bonds and foreign listings never appear. Options positions are excluded here rather than folded into the share counts. Political ownership is coming.